Safety of and Immune Response to Two Influenza Vaccines in HIV Infected Children and Adolescents
A Phase I/II Randomized Trial of the Safety and Immunogenicity of Cold Adapted Influenza Vaccine (FluMist) in HIV-Infected Children and Adolescents
調査の概要
状態
詳細な説明
Influenza virus infections are common among children, particularly during the winter season. The infections are often mild, but more serious cases can cause a number of complications, including respiratory illnesses and bacterial infections. HIV infected children may have an increased risk for developing influenza-related bacterial complications, and influenza infections among this population may lead to more rapid disease progression. The current standard of care for HIV infected children is vaccination with an inactivated influenza vaccine (IAIV). However, IAIV is limited in its ability to stimulate the immune systems of HIV infected children with advanced disease. FluMist, a cold-adapted live attenuated influenza vaccine, is both immunogenic and effective in HIV infected children; unfortunately, FluMist is associated with viral shedding, a period of time when the influenza virus used to produce the vaccine may be transmitted to other people. This study will compare the safety and immunogenicity of IAIV and FluMist in HIV infected children and adolescents. This study will also determine the prevalence and duration of FluMist viral shedding in HIV infected children and adolescents who have received the vaccination.
Participants in this study will be randomly assigned to one of two arms. Arm A participants will receive FluMist; Arm B participants will receive IAIV. A single immunization will occur on Day 0 of the study. Arm A participants will have study visits on Days 3, 14, and 28 or home visits on Days 3 and 14. Participants in Arm B will have a study visit on Day 28. A physical exam will be performed at the initial study visit; blood will be collected at study start and at each visit thereafter. Phone calls will be made to participants throughout the study. All participants will have a final study visit after 6 months.
研究の種類
入学
段階
- フェーズ2
- フェーズ 1
連絡先と場所
研究場所
-
-
Alabama
-
Birmingham、Alabama、アメリカ、35233
- UAB, Dept. of Ped., Div. of Infectious Diseases
-
Mobile、Alabama、アメリカ
- Univ. of South Alabama College of Medicine, Southeast Ped. ACTU
-
-
Arizona
-
Phoenix、Arizona、アメリカ、85006
- Phoenix Children's Hosp.
-
-
California
-
Long Beach、California、アメリカ、90801
- Long Beach Memorial Med. Ctr., Miller Children's Hosp.
-
Los Angeles、California、アメリカ、90033
- Usc La Nichd Crs
-
Los Angeles、California、アメリカ
- UCLA-Los Angeles/Brazil AIDS Consortium (LABAC) CRS
-
Oakland、California、アメリカ、94609-1809
- Children's Hosp. & Research Ctr. Oakland, Ped. Clinical Research Ctr. & Research Lab.
-
Orange、California、アメリカ、92868
- Children's Hosp. of Orange County
-
San Diego、California、アメリカ、92103
- UCSD Maternal, Child, and Adolescent HIV CRS
-
San Francisco、California、アメリカ、94143-0105
- UCSF Pediatric AIDS CRS
-
Torrance、California、アメリカ、90509
- Harbor - UCLA Med. Ctr. - Dept. of Peds., Div. of Infectious Diseases
-
-
Colorado
-
Aurora、Colorado、アメリカ
- Univ. of Colorado Denver NICHD CRS
-
-
Connecticut
-
Hartford、Connecticut、アメリカ
- Connecticut Children's Med. Ctr.
-
New Haven、Connecticut、アメリカ、06504
- Yale Univ. School of Medicine - Dept. of Peds., Div. of Infectious Disease
-
-
District of Columbia
-
Washington、District of Columbia、アメリカ、20010
- Children's National Med. Ctr., ACTU
-
Washington、District of Columbia、アメリカ、20060
- Howard Univ. Washington DC NICHD CRS
-
Washington、District of Columbia、アメリカ、20010
- Children's National Med. Ctr. Washington DC NICHD CRS
-
-
Florida
-
Fort Lauderdale、Florida、アメリカ、33316
- South Florida CDC Ft Lauderdale NICHD CRS
-
Fort Lauderdale、Florida、アメリカ
- Children's Diagnostic & Treatment Ctr. of South Florida
-
Gainesville、Florida、アメリカ、32610-0296
- Univ. of Florida College of Medicine-Dept of Peds, Div. of Immunology, Infectious Diseases & Allergy
-
Jacksonville、Florida、アメリカ、32209
- Univ. of Florida Jacksonville NICHD CRS
-
Miami、Florida、アメリカ、33136
- Univ. of Miami Ped. Perinatal HIV/AIDS CRS
-
Tampa、Florida、アメリカ、33620
- USF - Tampa NICHD CRS
-
-
Georgia
-
Augusta、Georgia、アメリカ
- Med. College of Georgia School of Medicine, Dept. of Peds., Div. of Infectious Diseases
-
Columbus、Georgia、アメリカ、31901
- Columbus Regional HealthCare System, The Med. Ctr.
-
-
Illinois
-
Chicago、Illinois、アメリカ、60614
- Chicago Children's CRS
-
Chicago、Illinois、アメリカ
- Univ. of Chicago - Dept. of Peds., Div. of Infectious Disease
-
Chicago、Illinois、アメリカ
- Mt. Sinai Hosp. Med. Ctr. - Chicago, Womens & Childrens HIV Program
-
-
Louisiana
-
New Orleans、Louisiana、アメリカ、70112-2699
- Tulane/LSU Maternal/Child CRS
-
-
Maryland
-
Baltimore、Maryland、アメリカ
- Johns Hopkins Hosp. & Health System - Dept. of Peds., Div. of Infectious Diseases
-
Baltimore、Maryland、アメリカ
- Univ. of Maryland Med. Ctr., Div. of Ped. Immunology & Rheumatology
-
-
Massachusetts
-
Boston、Massachusetts、アメリカ、02115
- HMS - Children's Hosp. Boston, Div. of Infectious Diseases
-
Boston、Massachusetts、アメリカ、02118
- BMC, Div. of Ped Infectious Diseases
-
Lawrence、Massachusetts、アメリカ、01841-2884
- Lawrence Family Health Ctr., Essex St. Clinic
-
Lowell、Massachusetts、アメリカ、01854
- Lowell Community Health Ctr.
-
Springfield、Massachusetts、アメリカ、01199
- Baystate Health, Baystate Med. Ctr.
-
Worcester、Massachusetts、アメリカ
- WNE Maternal Pediatric Adolescent AIDS CRS
-
-
Michigan
-
Detroit、Michigan、アメリカ、48201
- Children's Hospital of Michigan NICHD CRS
-
-
Missouri
-
Saint Louis、Missouri、アメリカ、63110
- Washington Univ. School of Medicine at St. Louis, St. Louis Children's Hosp.
-
-
New Jersey
-
Newark、New Jersey、アメリカ
- NJ Med. School CRS
-
-
New York
-
Bronx、New York、アメリカ、10457
- Bronx-Lebanon Hosp. IMPAACT CRS
-
Bronx、New York、アメリカ、10461
- Jacobi Med. Ctr. Bronx NICHD CRS
-
Bronx、New York、アメリカ、10461
- Jacobi Med. Ctr.
-
Brooklyn、New York、アメリカ、11203-2098
- SUNY Downstate Med. Ctr., Children's Hosp. at Downstate NICHD CRS
-
New York、New York、アメリカ、10016
- Nyu Ny Nichd Crs
-
New York、New York、アメリカ、10037
- Harlem Hosp. Ctr. NY NICHD CRS
-
New York、New York、アメリカ
- Columbia IMPAACT CRS
-
New York、New York、アメリカ、10029
- Mt. Sinai School of Medicine, Div. of Ped. Infectious Diseases
-
Rochester、New York、アメリカ、14642
- Strong Memorial Hospital Rochester NY NICHD CRS
-
Stony Brook、New York、アメリカ、11794-8111
- SUNY Stony Brook NICHD CRS
-
Syracuse、New York、アメリカ、13210
- SUNY Upstate Med. Univ., Dept. of Peds.
-
-
North Carolina
-
Chapel Hill、North Carolina、アメリカ、27599-7220
- UNC at Chapel Hill School of Medicine - Dept. of Peds., Div. of Immunology & Infectious Diseases
-
Durham、North Carolina、アメリカ、27705
- DUMC Ped. CRS
-
-
Pennsylvania
-
Philadelphia、Pennsylvania、アメリカ、19104-4318
- The Children's Hosp. of Philadelphia IMPAACT CRS
-
-
Tennessee
-
Memphis、Tennessee、アメリカ、38105-2794
- St. Jude/UTHSC CRS
-
-
Texas
-
Houston、Texas、アメリカ、77030
- Texas Children's Hosp. CRS
-
-
Virginia
-
Norfolk、Virginia、アメリカ、23507
- Children's Hosp. of the King's Daughters, Infectious Disease
-
-
Washington
-
Seattle、Washington、アメリカ、98105
- UW School of Medicine - CHRMC
-
Seattle、Washington、アメリカ、98105-0371
- Seattle Children's Hospital CRS
-
-
-
-
-
San Juan、プエルトリコ
- San Juan City Hosp. PR NICHD CRS
-
San Juan、プエルトリコ、00936-5067
- Univ. of Puerto Rico Ped. HIV/AIDS Research Program CRS
-
-
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- HIV infected
- Stable highly active antiretroviral therapy (HAART) regimen for at least 16 weeks with no changes in therapy anticipated
- Meet certain CD4 cell count and CD4% requirements
- Viral load of less than 60,000 copies/ml within 60 days prior to study start
- Received inactivated influenza vaccine (IAIV) in at least one of the past 2 years
- Written informed consent of parent or legal guardian
- Availability of parent or legal guardian to be contacted by phone
Exclusion Criteria:
- Immunosuppressive or immunomodulatory therapy within 60 days prior to immunization or immunological testing
- Aspirin or aspirin-containing therapy at the time of vaccination or planned within 42 days after immunization
- History of hypersensitivity to any component of IAIV or FluMist
- History of Guillain-Barre syndrome
- Receipt of any inactivated vaccine within 14 days prior to the study vaccination
- Receipt of any live vaccine within 30 days prior to the study vaccination
- Plans to receive any vaccine within the 30 days following the vaccination
- Receipt of any additional influenza vaccine for the duration of the study
- Prophylactic use of drugs with anti-influenza activity
- Moderate chronic pulmonary disease, obstructive or restrictive
- Cardiopulmonary disease affecting normal childhood activity
- Medically-diagnosed wheezing, bronchodilator use, or steroid use within the past 42 days
- Medical illness associated with suppression of T-cell immunity
- Pregnancy, breast-feeding, or unwillingness to use acceptable methods of contraception for 3 months following vaccination
- Severely immunosuppressed household member
- Receipt of any blood products within 3 months prior to vaccination or expected receipt during the study, including the 6-month follow-up period
- Significant fever or illness within 72 hours prior to vaccination
- Any other condition that would interfere with the study
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:防止
- 割り当て:ランダム化
- 介入モデル:並列代入
協力者と研究者
捜査官
- スタディチェア:Myron J. Levin, MD、University of Colorado, Denver
出版物と役立つリンク
一般刊行物
- Gunthard HF, Wong JK, Spina CA, Ignacio C, Kwok S, Christopherson C, Hwang J, Haubrich R, Havlir D, Richman DD. Effect of influenza vaccination on viral replication and immune response in persons infected with human immunodeficiency virus receiving potent antiretroviral therapy. J Infect Dis. 2000 Feb;181(2):522-31. doi: 10.1086/315260.
- Belshe RB, Mendelman PM, Treanor J, King J, Gruber WC, Piedra P, Bernstein DI, Hayden FG, Kotloff K, Zangwill K, Iacuzio D, Wolff M. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med. 1998 May 14;338(20):1405-12. doi: 10.1056/NEJM199805143382002.
- King JC Jr, Fast PE, Zangwill KM, Weinberg GA, Wolff M, Yan L, Newman F, Belshe RB, Kovacs A, Deville JG, Jelonek M; HIV Influenza Study Group. Safety, vaccine virus shedding and immunogenicity of trivalent, cold-adapted, live attenuated influenza vaccine administered to human immunodeficiency virus-infected and noninfected children. Pediatr Infect Dis J. 2001 Dec;20(12):1124-31. doi: 10.1097/00006454-200112000-00006.
- King JC Jr, Treanor J, Fast PE, Wolff M, Yan L, Iacuzio D, Readmond B, O'Brien D, Mallon K, Highsmith WE, Lambert JS, Belshe RB. Comparison of the safety, vaccine virus shedding, and immunogenicity of influenza virus vaccine, trivalent, types A and B, live cold-adapted, administered to human immunodeficiency virus (HIV)-infected and non-HIV-infected adults. J Infect Dis. 2000 Feb;181(2):725-8. doi: 10.1086/315246.
- Weinberg A, Song LY, Walker R, Allende M, Fenton T, Patterson-Bartlett J, Nachman S, Kemble G, Yi TT, Defechereux P, Wara D, Read JS, Levin M; IMPAACT P1057 Team. Anti-influenza serum and mucosal antibody responses after administration of live attenuated or inactivated influenza vaccines to HIV-infected children. J Acquir Immune Defic Syndr. 2010 Oct;55(2):189-96. doi: 10.1097/QAI.0b013e3181e46308.
研究記録日
主要日程の研究
研究の完了 (実際)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
キーワード
追加の関連 MeSH 用語
その他の研究ID番号
- P1057
- 10612 (その他の識別子:CTEP)
- PACTG P1057
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。